Category Archives: Medical

Abnormal vaginal bleeding is a symptom that should never be ignored. For one Malaysian patient, Ms. Lee, what initially seemed like a gynecological issue eventually led to the diagnosis of an extremely rare cancer: primary fallopian tube squamous cell carcinoma.

Her journey from Malaysia to Guangzhou, China reflects the importance of timely diagnosis, multidisciplinary evaluation, and personalized cancer treatment for international patients.

From Abnormal Bleeding to a Rare Cancer Diagnosis

Ms. Lee first noticed unexplained vaginal bleeding and visited a private doctor in Malaysia. After gynecological examination and cervical conization, her pathology report showed CIN III, also known as severe cervical dysplasia or carcinoma in situ of the cervix.

At that time, her doctor recommended a hysterectomy to prevent further progression. However, because the bleeding had stopped and she did not fully understand the seriousness of the condition, Ms. Lee chose to delay surgery.

Several months later, the bleeding returned. This time, she underwent total hysterectomy with bilateral salpingo-oophorectomy. The postoperative pathology report revealed a more serious condition:

• Well-differentiated keratinizing squamous cell carcinoma of the cervix
• Moderately differentiated squamous cell carcinoma in the right fallopian tube
• Tumor invasion extending to the right ovary
• Evidence suggesting primary fallopian tube squamous cell carcinoma

Primary fallopian tube carcinoma is already rare, accounting for a very small proportion of female genital tract malignancies. Squamous cell carcinoma of the fallopian tube is even rarer.

Why Fallopian Tube Cancer Is Difficult to Detect Early

Fallopian tube cancer can be difficult to diagnose in its early stages because symptoms are often nonspecific. It may be mistaken for gynecological inflammation, ovarian disease, or other pelvic conditions.

Patients should seek medical attention if they experience symptoms such as:

• Unexplained abnormal vaginal bleeding or discharge
• Persistent lower abdominal or pelvic pain
• Unexplained pelvic mass
• Abdominal bloating
• Urinary frequency
• Unexplained weight loss

Early evaluation is especially important for postmenopausal women or patients with recurrent abnormal bleeding.

Recurrence After Surgery and Chemotherapy

After surgery, Ms. Lee received six cycles of chemotherapy combined with targeted therapy. For a period of time, follow-up examinations showed no obvious tumor recurrence or metastasis.

However, in August and September 2025, two follow-up tests showed elevated CEA tumor marker levels. Further examination found small mesenteric lymph nodes and thickening of the right vaginal wall. Her doctor suspected recurrence.

This was a difficult moment for Ms. Lee. After completing another cycle of chemotherapy, she was physically weak and emotionally uncertain. At that time, a close friend introduced her to a public medical lecture related to cancer treatment in China.

After learning more and comparing different hospitals, Ms. Lee decided to seek further treatment in Guangzhou.

Seeking Treatment at Fuda Cancer Hospital in Guangzhou

In October 2025, Ms. Lee arrived in Guangzhou, China, and was admitted to the Fourth Department of Medicine at Fuda Cancer Hospital.

After admission, the hospital’s multidisciplinary team, also known as an MDT, reviewed her case carefully. Her pathology was re-examined and evaluated in detail. The final assessment was:

Recurrent stage IIIA2 right fallopian tube squamous cell carcinoma after surgery.

One important test result attracted the team’s attention: her PD-L1 immunohistochemistry TPS was ≥ 50%. This suggested that immunotherapy, particularly PD-1/PD-L1-related treatment, might be a potential option after comprehensive evaluation.

Personalized Treatment: TAI Combined with Immunotherapy

After multidisciplinary discussion, the medical team customized a treatment plan for Ms. Lee:

Transarterial Infusion Chemotherapy, also known as TAI, combined with immunotherapy.

TAI is a treatment method that delivers chemotherapy drugs directly into the arteries supplying the tumor area. Compared with conventional systemic chemotherapy, this approach may help increase the local drug concentration around the tumor while reducing some systemic side effects.

Immunotherapy works differently. Instead of directly attacking the tumor like chemotherapy, it helps activate the patient’s own immune system so immune cells can better recognize and attack cancer cells.

In Ms. Lee’s case, the treatment strategy combined local intervention with systemic immune support.

Encouraging Follow-Up Results

After six treatment cycles, Ms. Lee’s follow-up results showed encouraging changes:

• PET-CT showed no obvious signs of hypermetabolic malignant tumors
• Tumor remission was observed
• Tumor markers decreased to normal levels

These results suggested that the treatment was effective. Ms. Lee has continued maintenance therapy and follow-up care to help protect the progress she has achieved.

Her story is not simply about a “miracle.” It is about a patient who continued searching for treatment options during a difficult period and found a personalized approach through multidisciplinary care.

What International Patients Can Learn from This Case

Ms. Lee’s experience highlights several important points for cancer patients and families:

First, abnormal vaginal bleeding should not be ignored, especially when it happens repeatedly or after menopause.

Second, rare cancers often require careful pathological review and multidisciplinary consultation.

Third, for recurrent or complex cancer cases, personalized treatment planning may provide additional options beyond standard therapy.

Finally, international patients seeking cancer treatment in China should look for hospitals with multidisciplinary teams, experience in complex cases, and international patient support services.

About Fuda Cancer Hospital

Fuda Cancer Hospital, located in Guangzhou, China, provides cancer diagnosis and treatment services for both local and international patients. The hospital’s multidisciplinary teams evaluate complex cancer cases and design personalized treatment plans based on each patient’s condition, pathology, imaging results, tumor markers, and overall health status.

For international patients, coordinated medical support can help make the process of consultation, admission, treatment, and follow-up more manageable.

FAQ

What is fallopian tube cancer?

Fallopian tube cancer is a rare gynecological malignancy that starts in the fallopian tubes. Because early symptoms are often unclear, it may be difficult to diagnose at an early stage.

Is fallopian tube squamous cell carcinoma common?

No. Primary fallopian tube carcinoma itself is rare, and squamous cell carcinoma of the fallopian tube is an even rarer subtype.

What symptoms should patients pay attention to?

Patients should pay attention to abnormal vaginal bleeding, abnormal discharge, pelvic pain, abdominal bloating, pelvic mass, urinary frequency, or unexplained weight loss.

What treatment did the patient receive at Fuda Cancer Hospital?

According to the case, the patient received multidisciplinary evaluation followed by transarterial infusion chemotherapy combined with immunotherapy.

Can every patient receive the same treatment?

No. Cancer treatment must be based on the patient’s diagnosis, stage, pathology, biomarkers, imaging results, previous treatments, and overall physical condition. Patients should consult qualified medical professionals before making treatment decisions.

Medical Disclaimer

This article is for health education and case-sharing purposes only. It should not be used as a substitute for professional medical diagnosis or treatment. Individual treatment results may vary. Patients should consult qualified doctors for personalized medical advice.

Cardiovascular disease treatment is entering a new era. Doctors are no longer limited to symptom control alone. With better diagnosis, genetic testing, and targeted drugs, hospitals can now design more precise treatment plans for complex heart conditions.

At Shulan Hospital, this progress is already helping patients with difficult cardiovascular diseases. One important example is the treatment of hypertrophic obstructive cardiomyopathy, also known as HOCM.

This condition can block blood flow from the heart. It may cause chest discomfort, shortness of breath, low blood pressure, heart failure symptoms, and serious long-term risks. For some patients, conventional medication does not provide enough relief.

Shulan Hospital’s Department of Cardiology has explored a more precise approach. Through targeted therapy and multidisciplinary care, the team helped a patient with severe HOCM regain stability and quality of life.

What Is Hypertrophic Obstructive Cardiomyopathy?

Hypertrophic obstructive cardiomyopathy is a heart muscle disease. In this condition, part of the heart muscle becomes abnormally thick.

The thickened muscle can narrow the left ventricular outflow tract. This pathway allows blood to leave the heart and enter the body. When the pathway becomes blocked, the heart must work harder to pump blood.

Patients may experience fatigue, dizziness, chest tightness, shortness of breath, or symptoms of heart failure. Some patients may also have a family history, because hypertrophic cardiomyopathy can be related to genetic factors.

A key measurement in HOCM is the left ventricular outflow tract pressure gradient. A high gradient means the obstruction is serious. Doctors use echocardiography and other tests to evaluate this problem.

A Complex Case at Shulan Hospital

Mr. Jiang, a 68-year-old patient, had lived with hypertrophic obstructive cardiomyopathy for many years. More than ten years ago, he began to show symptoms of heart failure.

Six years ago, doctors implanted a cardiac resynchronization therapy pacemaker to support his heart function. However, his condition later worsened.

When he came to Shulan Hospital, the cardiology team performed a detailed evaluation. The results showed a serious obstruction. His myocardial thickness reached 26 millimeters. His left ventricular outflow tract pressure gradient reached 112 mmHg.

These numbers showed that his heart had great difficulty sending blood into the body.

Conventional treatment had limited effect. His blood pressure was too low, so doctors could not simply increase the medication dose. The team also considered chemical ablation. However, angiography showed that he did not have a suitable target vessel.

The treatment plan reached a difficult point.

Targeted Therapy Brought New Hope

At that time, a new targeted drug for hypertrophic obstructive cardiomyopathy was about to become available in Hangzhou. After discussion with the patient’s family, the cardiology team decided to try this treatment once it entered the market.

The team used the medication carefully. Doctors started with the minimum effective dose and monitored the patient closely.

One month later, the follow-up results showed clear improvement. His left ventricular outflow tract pressure gradient dropped from 112 mmHg to around 60 mmHg. His peripheral blood pressure also returned to a more stable level.

The patient felt more energetic. His family also noticed a visible change in his daily condition.

After that, Mr. Jiang returned to the hospital every four weeks for follow-up. Doctors used echocardiography, blood tests, and other indicators to monitor his progress. His cardiac function remained stable, and the obstruction improved.

Why Targeted Therapy Matters in Cardiology

Traditional treatment for hypertrophic cardiomyopathy often focuses on reducing symptoms. Doctors may use beta-blockers and other medications to slow the heart rate and reduce the workload of the heart.

Some patients may need septal reduction therapy or surgery. However, these options may carry higher risk, especially for older patients or people with multiple health problems.

Targeted therapy offers another direction. It focuses more directly on the disease mechanism. In hypertrophic cardiomyopathy, certain genetic and protein-level abnormalities can affect heart muscle contraction.

By acting on specific targets, new therapies may help reduce obstruction and improve cardiac function. This does not mean every patient can use targeted drugs. Doctors still need careful diagnosis, risk evaluation, and long-term monitoring.

But for selected patients, targeted therapy may provide new possibilities.

Multidisciplinary Care for a High-Risk Patient

Mr. Jiang’s treatment was complex because he did not only have heart disease. He also had long-term liver disease related to schistosomiasis, which had progressed to cirrhosis.

Cirrhosis increased his risk of esophageal and gastric variceal bleeding. After his blood pressure improved, the pressure in fragile vessels also became a concern.

In April, he had an episode of gastrointestinal bleeding. Doctors controlled the condition with conservative treatment. Later, he developed a more serious bleeding event and hemorrhagic shock.

The situation became critical.

Shulan Hospital quickly organized a multidisciplinary consultation. The team included specialists from cardiology, infectious diseases, interventional vascular surgery, gastroenterology, and anesthesiology.

After careful assessment, the team decided to perform an emergency TIPS procedure. TIPS stands for transjugular intrahepatic portosystemic shunt. This procedure helps reduce portal venous pressure and control variceal bleeding.

The operation carried high risk because the patient had recently improved heart function and was in shock. The team monitored his heart rate, blood pressure, and vital signs throughout the procedure.

After more than two hours, the operation achieved successful hemostasis.

Recovery and Long-Term Management

After surgery, the infectious diseases team created a new anti-infection plan. The goal was to reduce complications related to cirrhosis, weak immunity, and postoperative recovery.

The team also worked to prevent hepatic encephalopathy and cardiac insufficiency. After more than one month of rehabilitation, the patient’s gastrointestinal bleeding was controlled.

This case shows why multidisciplinary care is important. A patient with complex disease rarely needs only one treatment. Heart disease, liver disease, bleeding risk, infection risk, and rehabilitation all affect the final outcome.

For Mr. Jiang, targeted therapy improved the core cardiac problem. Then multidisciplinary care helped him survive a later emergency.

Precision Diagnosis Comes Before Precision Treatment

Targeted therapy does not fit every patient. Before doctors use this kind of treatment, they need a precise diagnosis.

This may include blood tests, cardiac imaging, echocardiography, genetic testing, and specialist evaluation. Doctors need to understand the cause of the disease before they choose a therapy.

In cardiovascular medicine, this approach is becoming more important. Some patients need protein-level targeted drugs. Others may benefit from RNA-level therapies or future gene-level treatments.

This shift may change how doctors manage inherited cardiovascular diseases, familial hyperlipidemia, and certain types of cardiomyopathy.

Shulan Hospital’s Approach to Advanced Cardiovascular Care

Shulan Hospital’s cardiology team focuses on both advanced treatment and whole-person care. The hospital does not only treat one symptom. It evaluates the patient’s full condition and builds a coordinated plan.

For patients with complex heart disease, this approach can be especially valuable. They may need cardiology, imaging, interventional treatment, intensive care, hepatology, infectious disease care, and rehabilitation support.

The case of Mr. Jiang reflects this model. It combines targeted cardiovascular therapy, careful monitoring, emergency intervention, and multidisciplinary cooperation.

Conclusion

Targeted therapy for hypertrophic obstructive cardiomyopathy is changing the future of cardiovascular care. It gives selected patients a new option when conventional treatment is not enough.

At Shulan Hospital, the successful management of a complex HOCM case shows the value of precision medicine. It also shows the importance of multidisciplinary care for patients with multiple high-risk conditions.

For patients with unexplained heart failure symptoms, chest discomfort, shortness of breath, or a family history of cardiomyopathy, early evaluation is important. A timely diagnosis can open the door to more personalized treatment options.

As cardiovascular medicine continues to advance, targeted therapy may help more patients achieve better outcomes and a better quality of life.

India, long celebrated as a global hub for affordable, world-class medical care, is increasingly under fire for a darker reality lurking beneath its booming medical-tourism industry. Behind the glossy brochures and five-star hospital lobbies lies a rampant black market for illegal organ transplants, where foreign patients are lured, lied to, and left financially and physically devastated.

From Myanmar to Bangladesh, Cambodia to the Middle East, desperate patients seeking life-saving kidney and liver transplants are being trafficked into India under false promises, only to find themselves trapped in a web of forged documents, fake familial ties, and exploitative brokers—often with the complicity of top Indian hospitals and the star surgeons who headline their marketing posters.